Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

follow-up to its marketed JAK inhibitor Xeljanz (tofacitinib). ... And for good measure Pfizer is developing a topical formulation of Xeljanz for atopic dermatitis, an approach also taken by Torii Pharma with its phase II candidate JTE-052.

Latest news

BMS psoriasis drug hits the mark in phase II

Pfizer’s Xeljanz (tofacitinib) has been approved for psoriatic arthritis but was turned down by the FDA for psoriasis in 2015.
Gilead and Galapagos JAK contender scores in RA trial

The first JAK inhibitor on the market is Pfizer’s Xeljanz (tofacitinib) and already earns in excess of $1bn a year in RA revenues.
Gilead, Galapagos JAK inhibitor clears phase II test

related. First-to-market JAK inhibitor Xeljanz (tofacitinib) from Pfizer has already achieved $1bn-plus sales in RA, and with Olumiant somewhat hamstring by the safety issue on its label analysts
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

Xeljanz approved in ulcerative colitis. Meanwhile, in its 'innovative health' medicines division, Pfizer has also gained a new approval for Xeljanz. ... Xeljanz has been slow to gain market share since it was launched in 2012, despite it being the only
Pfizer CEO reckons rebates will disappear, and that’s a positive

Pfizer’s chief executive Ian Read (pictured below) has said that he expects drug price rebates will eventually disappear in the US, and that could give drugs like arthritis drug Xeljanz ... formulary is offering a large rebate – something that Read

More from news
Approximately 17 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Medical Writer: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Health Policy – Global Agency: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Manager / Account Director: Competative

Global Business Development Director – Health Education: excellent commission

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Associate Director: £75, 000-90, 000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...